Bernhard Hauns

711 total citations
21 papers, 429 citations indexed

About

Bernhard Hauns is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Bernhard Hauns has authored 21 papers receiving a total of 429 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 10 papers in Oncology and 6 papers in Genetics. Recurrent topics in Bernhard Hauns's work include Chronic Lymphocytic Leukemia Research (6 papers), Cancer Treatment and Pharmacology (6 papers) and Histone Deacetylase Inhibitors Research (5 papers). Bernhard Hauns is often cited by papers focused on Chronic Lymphocytic Leukemia Research (6 papers), Cancer Treatment and Pharmacology (6 papers) and Histone Deacetylase Inhibitors Research (5 papers). Bernhard Hauns collaborates with scholars based in Germany, Italy and United States. Bernhard Hauns's co-authors include Róbert Hermann, Thomas D. Bethke, Christoph H. Gleiter, Dietrich Knoerzer, Richard Fux, Klaus Mörike, Michael D. David, W Wurst, Israel Arango‐Hisijara and Karl Zech and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Analytical Biochemistry.

In The Last Decade

Bernhard Hauns

21 papers receiving 409 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bernhard Hauns Germany	10	212	138	132	115	74	21	429
Roxanne Steinle United States	9	130 0.6×	99 0.7×	57 0.4×	99 0.9×	27 0.4×	14	351
Xinan Wang China	11	189 0.9×	25 0.2×	41 0.3×	54 0.5×	47 0.6×	35	384
J. P. Eder United States	10	143 0.7×	34 0.2×	50 0.4×	148 1.3×	80 1.1×	21	418
Jean‐Michel Luccarini France	11	213 1.0×	64 0.5×	85 0.6×	40 0.3×	52 0.7×	16	471
H Gaitantzi Germany	10	148 0.7×	42 0.3×	82 0.6×	74 0.6×	13 0.2×	16	420
Albert Cornelius United States	10	300 1.4×	48 0.3×	188 1.4×	45 0.4×	111 1.5×	28	523
Chi-Chung Chan China	10	155 0.7×	31 0.2×	100 0.8×	151 1.3×	126 1.7×	24	414
Cen Chang China	14	245 1.2×	47 0.3×	33 0.3×	72 0.6×	24 0.3×	37	552
Laurie Iciek United States	5	218 1.0×	20 0.1×	57 0.4×	78 0.7×	20 0.3×	7	407
Alessandra Cocomazzi Italy	11	116 0.5×	29 0.2×	31 0.2×	106 0.9×	72 1.0×	17	363

Countries citing papers authored by Bernhard Hauns

Since Specialization

Citations

This map shows the geographic impact of Bernhard Hauns's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernhard Hauns with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernhard Hauns more than expected).

Fields of papers citing papers by Bernhard Hauns

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernhard Hauns. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernhard Hauns. The network helps show where Bernhard Hauns may publish in the future.

Co-authorship network of co-authors of Bernhard Hauns

This figure shows the co-authorship network connecting the top 25 collaborators of Bernhard Hauns. A scholar is included among the top collaborators of Bernhard Hauns based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernhard Hauns. Bernhard Hauns is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Buske, Christian, Alessandra Tedeschi, Judith Trotman, et al.. (2021). Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study. Journal of Clinical Oncology. 40(1). 52–62. 64 indexed citations

Noy, Ariela, Sven de Vos, Morton Coleman, et al.. (2020). Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. Blood Advances. 4(22). 5773–5784. 63 indexed citations

Buske, Christian, Alessandra Tedeschi, Judith Trotman, et al.. (2020). Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATETM Study. Blood. 136(Supplement 1). 24–26. 18 indexed citations

Hájek, Roman, Luděk Pour, Muhıt Özcan, et al.. (2019). A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. European Journal Of Haematology. 104(5). 435–442. 12 indexed citations

Tedeschi, Alessandra, Meletios Α. Dimopoulos, Judith Trotman, et al.. (2019). Patient-reported outcomes (PROs) with ibrutinib-rituximab in Waldenström macroglobulinemia (WM): Results from iNNOVATE.. Journal of Clinical Oncology. 37(15_suppl). 8018–8018. 1 indexed citations

Miklos, David B., Madan Jagasia, Hildegard Greinix, et al.. (2017). A randomized, double-blind phase III study of ibrutinib versus placebo in combination with corticosteroids in patients with new onset chronic graft versus host disease.. Journal of Clinical Oncology. 35(15_suppl). TPS7072–TPS7072. 4 indexed citations

Mross, K., Heike Richly, Sebastian Bauer, et al.. (2015). Overcoming the proliferation rate paradox: Clinical evaluation of a continuous dosing scheme of the novel oral Eg5 inhibitor 4SC-205.. Journal of Clinical Oncology. 33(15_suppl). 2528–2528. 3 indexed citations

Tresckow, Bastian von, Dennis A. Eichenauer, Walter E. Aulitzky, et al.. (2014). First-in-human study of 4SC-202, a novel oral HDAC inhibitor in advanced hematologic malignancies (TOPAS study).. Journal of Clinical Oncology. 32(15_suppl). 8559–8559. 8 indexed citations

Mross, K., Heike Richly, Annette Frost, et al.. (2014). First-in-human study of 4SC-205 (AEGIS), a novel oral inhibitor of Eg5 kinesin spindle protein.. Journal of Clinical Oncology. 32(15_suppl). 2564–2564. 10 indexed citations

10.

Brunetto, André T., Joo Ern Ang, Rohit Lal, et al.. (2013). First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 19(19). 5494–5504. 41 indexed citations

11.

Bitzer, Michael, Tom M. Ganten, Jens T. Siveke, et al.. (2013). Resminostat in advanced hepatocellular carcinoma (HCC): Overall survival subgroup analysis of prognostic factors in the SHELTER trial.. Journal of Clinical Oncology. 31(15_suppl). e15088–e15088. 7 indexed citations

12.

Schulze‐Bergkamen, Henning, Dirk Jaeger, Hans‐Georg Kopp, et al.. (2013). Phase I dose escalation of the oral histone deacetylase inhibitor (HDACi) resminostat in combination with FOLFIRI in colorectal cancer (CRC) patients: The SHORE trial.. Journal of Clinical Oncology. 31(15_suppl). 3625–3625. 1 indexed citations

13.

Bitzer, Michael, Marius Horger, Tom M. Ganten, et al.. (2012). Investigation of the HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC): Clinical data from the phase I/II SHELTER study.. Journal of Clinical Oncology. 30(4_suppl). 262–262. 6 indexed citations

14.

Bitzer, Michael, Marius Horger, Tom M. Ganten, et al.. (2012). Efficacy, safety, tolerability, and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): Phase II SHELTER study.. Journal of Clinical Oncology. 30(15_suppl). 4115–4115. 8 indexed citations

15.

Hauns, Bernhard, et al.. (2011). Phase II Study with 5-Fluorouracil and Ginkgo biloba Extract (GBE 761 ONC) in Patients with Pancreatic Cancer. Arzneimittelforschung. 49(12). 1030–1034. 9 indexed citations

16.

Walewski, Jan, Ewa Paszkiewicz‐Kozik, Gabriela Borsaru, et al.. (2010). Resminostat In Relapsed or Refractory Hodgkin Lymphoma: Initial Results of the SAPHIRE Phase II Trial with a Novel Oral Histone Deacetylase (HDAC) Inhibitor.. Blood. 116(21). 2811–2811. 6 indexed citations

17.

Hermann, Róbert, Werner Siegmund, Thomas Gießmann, et al.. (2007). The Oral, Once‐Daily Phosphodiesterase 4 Inhibitor Roflumilast Lacks Relevant Pharmacokinetic Interactions With Inhaled Budesonide. The Journal of Clinical Pharmacology. 47(8). 1005–1013. 18 indexed citations

18.

Bethke, Thomas D., Róbert Hermann, Bernhard Hauns, et al.. (2006). Dose‐Proportional Intraindividual Single‐ and Repeated‐Dose Pharmacokinetics of Roflumilast, an Oral, Once‐Daily Phosphodiesterase 4 Inhibitor. The Journal of Clinical Pharmacology. 47(1). 26–36. 75 indexed citations

19.

Hauns, Bernhard, Róbert Hermann, Rolf Herzog, et al.. (2006). Investigation of a Potential Food Effect on the Pharmacokinetics of Roflumilast, an Oral, Once‐Daily Phosphodiesterase 4 Inhibitor, in Healthy Subjects. The Journal of Clinical Pharmacology. 46(10). 1146–1153. 37 indexed citations

20.

Brouwer, Eric, Jaap Verweij, Bernhard Hauns, et al.. (1998). Linearized Colorimetric Assay for Cremophor EL: Application to Pharmacokinetics after 1-Hour Paclitaxel Infusions. Analytical Biochemistry. 261(2). 198–202. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact